Show simple item record

dc.contributor.authorWorld Health Organization, Regional Office for South-East Asia
dc.coverage.spatialNew DelhiEN
dc.date.accessioned2014-07-19T09:59:22Z
dc.date.available2014-07-19T09:59:22Z
dc.date.copyrightWorld Health Organization
dc.date.issued2012-07-19
dc.identifier.govdocSEA/RC65/11
dc.identifier.urihttp://www.who.int/iris/handle/10665/128317
dc.description.abstractSince 1957, influenza viruses have been shared by Member States through the WHO Global Influenza Surveillance and Response network (‎GISRS)‎; but in 2007 issues were raised about how this might be linked to access to vaccines and other benefits. To address these issues, the World Health Assembly resolution WHA60.28 recommended the Director-General to:  develop a framework and mechanism for benefit sharing;  establish an international stockpile of influenza A (‎H5N1)‎ vaccine; and  prepare guidance on vaccine distribution. The resulting Pandemic Influenza Preparedness Framework (‎PIP Framework)‎ is expected to enhance the capacity for surveillance, risk assessment and early warning. The PIPFW also aims to prioritize financial and “in kind” benefits to developing (‎H5N1 affected)‎ countries that lack capacity to produce/access influenza vaccines, diagnostics and pharmaceuticals according to public health risk and needs (‎i.e. there will be a structured approach to a proportional allocation of the benefit to Member States)‎. The financial component of the expected benefit (‎the Partnership Contribution)‎ is expected to be US$ 28 million per year. To date, negotiation has been commenced by the WHO Secretariat with only a single “third party” (‎GSK)‎, although discussions with others may start soon. In order to implement the PIP Framework at national level, Member States should continue to share influenza viruses with pandemic potential with a WHO reference laboratory of their choice. Transfer of influenza viruses and products derived from them (‎also referred to as PIP Biological Materials)‎ is governed by type 1 and type 2 Standard Material Transfer Agreements (‎SMTAs)‎. Type 1 SMTAs govern the transfer of viruses from National Influenza Centres to GISRS laboratories, so their adoption is a part of national implementation. Type 2 SMTAs govern the transfer of viruses to third parties (‎typically manufacturers of vaccines and pharmaceuticals)‎. Although Member States have no direct role in negotiation of these agreements, they may wish to be aware of how negotiations are proceeding, and how the ensuing benefits are expected to be allocated. Member States may also consider advocating for a mechanism to allow their needs to be more directly articulated to the Advisory Group/Secretariat in order to inform decisions about the allocation of benefit, and the negotiation of “in kind” benefits/technology transfer. The High-Level Preparatory (‎HLP)‎ Meeting held in the Regional Office in New Delhi from 2 to 5 July 2012 reviewed the working paper and made the following recommendations: Action by Member States  To ensure that laboratories concerned continue to share influenza viruses in a timely manner, including those with pandemic potential. Actions by WHO-SEARO  To accelerate the process of negotiating “type 2” SMTAs.  To advocate for flexibility in the proportional distribution of funds according to identified needs in order to ensure optimal use of resources from the Partnership Contribution.  To strengthen national influenza centres and WHO collaborating centres. The working paper and the HLP Meeting recommendations are submitted to the Sixty fifth Session of the Regional Committee for its consideration.EN
dc.languageEnglish
dc.language.isoenEN
dc.publisherWHO Regional Office for South-East AsiaEN
dc.titleSEA/RC65/11 - Reports of WHO global working/advisory groups: Pandemic Influenza Preparedness (‎PIP)‎EN
dc.typeGoverning body documentsEN


Files in this item

Thumbnail

This item appears in the following Collection(‎s)‎

Show simple item record